What 12+ Years of Adherence Data Reveals About Metabolic Therapy Persistence

Despite significant advances in diabetes and metabolic therapies, long-term persistence remains one of the biggest challenges facing pharmaceutical organizations.

Most patient support programs are designed to address a common assumption: patients stop taking medication because they forget. But real-world data tells a different story.

After analyzing 130+ behavioral signals per patient across millions of managed doses and more than 12 years of real-world adherence data, Medisafe identified predictable behavioral patterns that influence whether patients stay engaged with therapy over time. The findings reveal that long-term patient persistence isn’t shaped by forgetfulness, but rather a combination of behavioral, environmental, and treatment-related factors. 

Metabolic Adherence Is Behavioral

Across metabolic patient populations, Medisafe's analysis uncovered several notable trends:

• Adherence declines as dosing frequency increases, highlighting the impact of treatment burden.
• Dosage fluctuates throughout the week, with adherence rates varying by day of the week and time of day.
• Patients who add a support partner via Medisafe’s Medfriend average a 71% of improved adherence 

These patterns reveal predictable behavioral signals that can be identified and addressed through more personalized, effective interventions.

The opportunity is significant. While average medication adherence across therapeutic categories hovers around 50%, metabolic patients who receive behavior-driven support demonstrate substantially stronger engagement with therapy.

Why Traditional Engagement Falls Short

Many patient support programs rely on static reminders, generic educational content, or predetermined outreach schedules. The challenge is that adherence risk is dynamic.

Patients move in and out of periods of therapy abandonment risk based on their treatment journey, behavior patterns, and changing needs. Without visibility into those signals, support programs struggle to intervene at the right time.

Turning Behavioral Intelligence Into Better Outcomes

Medisafe's engagement engine is built on real-world behavioral data collected across millions of patient journeys.

By identifying therapy-specific adherence patterns and behavioral risk signals, Medisafe helps pharmaceutical organizations deliver more personalized interventions, optimize engagement timing, and support patients throughout the treatment journey in real-time.

The result is a more proactive approach to patient support designed to strengthen adherence, improve persistence, and maximize the value of metabolic therapies.

New Research: The Behavioral Drivers of Metabolic Adherence

Our latest analysis explores how treatment complexity, daily routines, therapy type, and social support influence adherence across metabolic patient populations.

The findings offer practical insights for pharmaceutical teams looking to strengthen patient support programs, improve persistence, and maximize the impact of metabolic therapies.

‍

Want to see more of the behavioral patterns shaping persistence?

Book a Strategy Session.